Artificial bone graft substitutes for curettage of benign and low-grade malignant bone tumors: clinical and radiological experience with Cerasorb

doi:10.21203/rs.3.rs-1509900/v1

Download PDF

Article

Artificial bone graft substitutes for curettage of benign and low-grade malignant bone tumors: clinical and radiological experience with Cerasorb

https://doi.org/10.21203/rs.3.rs-1509900/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Artificial bone graft substitutes (ABGS) for curettage of bone tumors are becoming increasingly popular. The aim of this retrospective analysis was to determine the efficacy of the ABGS Cerasorb (Curasan-AG, Kleinostheim, Germany), a beta-tricalcium phosphate (beta-TCP), concerning resorption profile, bone healing and remodeling after surgery and to evaluate potential complications. 43 patients suffering from benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity using the ABGS Cerasorb between 2018 and 2021 and included in the final analysis. Clinical follow-up exams with x-rays in two planes were performed six weeks, three months, six months and one year after surgery. After a mean follow-up period of 14.6 months, radiological consolidation following curettage was observed in all patients. Total resorption was observed in 16.3% of patients; in the other 83.7%, resorption was partial. In four patients, of whom two had a tumor in the distal femur and two in the humeral diaphysis, fractures occurred within six weeks after primary surgery. In conclusion, the beta-TCP Cerasorb seems to be a reliable bone graft substitute with low complication rates and is a suitable alternative to autologous bone grafts or allografts. Nonetheless, it shows a tendency of delayed resorption.

Benign and low-grade malignant bone tumors are usually treated with intralesional curettage. Subsequently, the bony cavity can be left empty or it can be filled with autologous or allogenic materials. The aim of filling with grafts is full bony ingrowth and remodeling into mature bone^1,2. Surgical adjuvants such as artificial bone graft substitutes (ABGS) have become increasingly popular, as they do not involve donor site morbidity. Known side effects of harvesting autologous bone grafts from the iliac crest include risk of infection, delayed wound healing, neuro-vascular injuries, heterotopic ossification and local pain^2,3. On the other hand, allogenic materials have been reported to be immunogenic and might transfer infectious diseases, with complication rates for infection of up to 12.2%^4,5.

Several ABGS are available, including demineralized bone matrix, bone graft extenders, and bone morphogenic proteins. Demineralized bone matrix contains proteins gained from processed cadaver bone without minerals. Bone morphogenic proteins induce new bone formation by stimulating osteoblastic differentiation. Bone graft extenders comprise ceramics (e.g., hydroxyapatite), salts (e.g., calcium sulphate, tricalcium phosphate), and synthetic products such as polymethylmethacryclate (PMMA). They are shapeable and therefore can be used to fill irregularly shaped defects. Moreover, they are accessible unrestrictedly and do not involve the risk of transmitting infectious diseases^2,6−10. Tricalcium phosphates (TCP) are characterized by their biocompatibility, favorable resorption properties and osteoconductivity^11,12.

Cerasorb (Curasan-AG, Kleinostheim, Germany) is a pure-phase beta-tricalcium phosphate (β-TCP) with precisely defined physical and chemo-crystalline properties and a high level of uniformity of chemical composition and purity. In contrast to alpha-tricalcium phosphates (α-TCP), β-TCP is thermodynamically stable in a biological environment and within a normal temperature range. Biodegradation is faster than that of α-TCP^{13 − 15}.

The aim of this retrospective analysis was to determine the efficacy of the artificial bone graft substitute Cerasorb concerning resorption profile, bone healing and remodeling after surgery and to evaluate potential complications.

Altogether, 43 patients who had received curettage of benign or low-grade malignant bone tumors and filling with the ABGS Cerasorb were included in this study. The study cohort consisted of 21 male and 22 female patients. Patients’ mean age at surgery was 42 years (range, 15–70 years). 17 lesions were located in the distal femur, one was in the femoral diaphysis, one was in the proximal fibula, three lesions were in the proximal tibia, one in the distal tibia, one was in the acetabulum, two in the metacarpal bones and one in the medial phalanx of the fifth finger, three lesions were in the proximal femur, four were located in the humeral diaphysis and nine lesions were located in the proximal humerus. A summary of tumor locations is depicted in Fig. 1. The tumor entities comprised enchondromas, simple or juvenile bone cysts, atypical cartilaginous tumors, chondroblastomas, one case of Langerhans cell histiocytosis, one intraosseous ganglion, fibrous dysplasia and a case of Rosai-Dorfman syndrome, the frequency of which is presented graphically in Fig. 2. The mean filling volume applied to the bony cavities was 40.2 ml (range, 5-100 ml). The mean maximum diameter of the lesions was 5.6 cm (range, 1.8–14.5)

According to the bone healing classification system by Neer et al.^18,19, all lesions were grade I lesions, indicating that curetted tumors require no further treatment. The study collective included no grade II, III or IV lesions. However, in nine cases, an additional plate osteosynthesis was performed in order to achieve more stable conditions. In two patients, an additional structural allograft was added. This was decided intraoperatively by the performing surgeon.

After a mean follow-up period of 14.6 months, radiological consolidation of the cortex following curettage was observed in all patients after viewing standardized postoperative x-rays, which were performed six weeks, three months, 6 months and 12 months after surgery. In case of doubt, consolidation was confirmed by an expert bone radiologist (J.I.). Cerasorb was totally resorbed in five patients (16.3%), altogether, as outlined in Figs. 3A and 3B. In the remaining patients (83.7%), partial resorption was observed, leaving the ABGS still clearly visible, as shown in Figs. 4A and 4B.

In four patients, of whom two had a tumor in the distal femur and two in the humeral diaphysis, fractures occurred within six weeks after primary surgery, as outlined exemplarily in Figs. 5A and 5B. These lesions were rather large, with maximum diameters of 4.8 cm and 5.0 cm in the distal femur and 6 cm and 11 cm in the humeral diaphysis. In these cases, uncomplicated revision surgery with plate osteosynthesis was performed, which is shown exemplarily in Fig. 5C. No other complications were observed during the follow-up period. According to the classification system by Goslings and Gouma¹⁷, the complications reported can be summarized as follows: none of the patients suffered grade 0, I, III, IV or V complications. Two patients presented with grade II complications, but showed total recovery after revision surgery. No local recurrences were observed during follow-up.

One of the most important findings of this study was that the ABGS Cerasorb is associated with adequate and fast bone consolidation and long durability. Moreover, the complication rate is rather small. Also, a minimal invasive, percutaneous approach would be possible, as performed frequently for instance in case of vertebroplasty or kyphoplasty. In theory, according to the instructions for use, the resilience of Cerasorb is supposed to allow for an unrestricted postoperative mobilization protocol. In the authors’ opinion, more restricted postoperative protocols have to be applied, depending on the individual case, defect size and stability of the construct.

Complications associated with curettage and filling found in this study were due to a limited stability of the construct, leading to fractures when application was performed in a weightbearing bone, such as at the humeral diaphysis or the distal femur. In all cases, uncomplicated plate osteosynthesis was performed and healing was proper. However, little is known about stability and fractures after curettage and filling and thus, an important topic of future research will lie in the determination of stability properties of a tumor site, such as size and location, that necessitate the use of protective plate osteosynthesis in order to avoid the occurrence of fractures. Hirn et al.²⁰ found a strong correlation between size and volume of the tumor and postoperative fracture occurrence. Kundu et al.²¹ proved that there was a correlation between size, volume and localization of the tumor and the risk of postoperative fracture. A retrospective case-series performed by Perisano et al.²² in 2016 focused on indications for prophylactic osteosynthesis associated with the curettage of benign and low-grade malignant bone tumors in the distal femur. They analyzed 12 patients treated by a single surgeon and recommended preventive osteosynthesis after curettage in case of very large lesions (> 5 cm, > 60 ccm) or high functional requirements, in obese patients and always, when local adjuvants such as ABGS were used. Moreover, studies showed that leaving the cavity unfilled involves an even higher risk of postoperative fracture and that the use of bone cement for filling yields the second highest fracture risk^20,23,24.

In 2017, Friesenbichler et al.²⁵ performed a prospective, non-randomized study on 27 patients treated with the α-TCP Calcibon (Biomet, Warsaw, IN) in granular form for filling bony cavity defects after curettage of benign or low-grade malignant bone tumors with an average postoperative follow-up of 26 months. Radiological consolidation was observed in 23 patients after a mean follow-up of six months. Nonetheless, resorption was not seen by that time or even after 32 months of follow-up. Moreover, no local recurrences occurred. The findings of this study were similar to those depicted in the present study, although with Cerasorb, complete resorption occurred in 16.3% of patients after a mean follow-up of 14.6 months. This is in line with current literature, as the ABGS Calcibon is similar to Cerasorb, but belongs to the group of α-TCPs, which are associated with a similar degree of solubility, but a slower biodegradation¹⁴.

In 2006, Hirata et al.²⁶ analyzed 53 patients with benign bone tumors who had undergone curettage and filling with β-TCP. In their patient collective, complete resorption rates of the β-TCP were higher than in the present study, even though the follow-up time was comparable.

There were several limitations associated with the present study. First, data collection was performed retrospectively. Second, the mean follow-up period was only 14.6 months, which is quite a short interval, so that long-term effects and time to full resorption in those patients where resorption was not complete after the end of follow-up are missing. This shows that in order to capture the full resorption profile of the ABGS Cerasorb, a longer follow-up interval is definitely needed in future research. Third, the patient collective was rather small and heterogenous, as a lot of different tumor entities localized in different bones were included. Moreover, mostly due to the high heterogeneity of data, the analysis was purely descriptive and statistical analysis could not be performed.

In conclusion, based on our short-term observation, the β-TCP Cerasorb seems to be a reliable bone graft substitute with low complication rates and is a suitable alternative to autologous bone grafts or allografts. Nonetheless, it shows a tendency of delayed resorption.

At the initial phase of patient recruitment, 55 potential patients with benign and low-grade malignant bone tumors treated at a single center between November 2018 and July 2021 with curettage and filling with Cerasorb were found. However, 12 patients were lost for follow-up within the first four months after surgery, eventually leaving 42 patients for analysis, who were included in this study and retrospectively reviewed. The study was approved by the ethics committee of the Medical University of Graz (EK 34–139 ex 21/22) prior to conduction of the study. Only patients with benign and low-grade malignancies were included. Clinical follow-up exams with x-rays in two planes were performed six weeks, three months, six months and twelve months after surgery. All surgeries were carried out by experienced orthopedic tumor surgeons.

Following surgical exposure of the affected bone, an osseous window was created in order to gain access to the lesion. Curettage was performed under fluoroscopic visualization using a c-arm. The curetted tissue was sent for histopathological examination. All diagnostic evaluations were performed by expert bone tumor pathologists and classified by the WHO Classification for Bone and Soft Tissue Tumors 2020¹⁶. The ABGS was prepared according to the respective manufacturer's instructions, injected into the cavity and allowed to dry for several minutes. Subsequently, the osseous window was re-attached. In 13 patients, a protective plate osteosynthesis was performed in order to enhance stability. Finally, the layers of the wound were closed.

Parameters assessed in this study included time required for osseous consolidation and resorption, local recurrence rates, and complications. Surgical complications were reported according to the classification system by Goslings and Gouma¹⁷ as follows: 0 (no harm), 1 (temporary disadvantage, no reoperation), 2 (recovery after reoperation), 3 (permanent damage/disability), 4 (death), and 5 (unclear as a result of untimely death). Assessment of osseous integration, resorption and bony healing was performed according to the modified Neer score^18,19.

Author contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by U.W., J.F. and S.S. Specific radiological and histopathological results were reviewed by J.I. and B.L. The first draft of the manuscript was written by U.W. and all other authors (J.F., S.S., A.L., M.B., J.I., B.L.) commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Data availability statement

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Additional information

Competing interests

The authors declare no competing interests.

Ethics approval and informed consent

The study was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Clinical Practice. The study was approved by the ethics committee of the Medical University of Graz prior to conduction of the study (EK 34-139 ex 21/22). Informed consent was obtained from all participating patients prior to conduction of the study.

Funding

No external funding was used.

Friesenbichler, J. et al. Adverse reactions of artificial bone graft substitutes: lessons learned from using tricalcium phosphate geneX(R). Clin. Orthop. Relat. Res. 472, 976–982 (2014).
Van Hoff, C. et al. Effectiveness of ultraporous beta-tricalcium phosphate (vitoss) as bone graft substitute for cavitary defects in benign and low-grade malignant bone tumors. Am. J. Orthop. 41, 20–23 (2012).
Kurz, L. T., Garfin, S. R. & Booth, R. E. Jr. Harvesting autogenous iliac bone grafts. A review of complications and techniques. Spine. 14, 1324–1331 (1989).
Tomford, W. W., Starkweather, R. J. & Goldman, M. H. A study of the clinical incidence of infection in the use of banked allograft bone. J. Bone Joint Surg. Am. 63, 244–248 (1981).
Sutherland, A. G., Raafat, A., Yates, P. & Hutchison, J. D. Infection associated with the use of allograft bone from the north east Scotland Bone Bank. J. Hosp. Infect. 35, 215–222 (1997).
Evaniew, N. et al. Use of a calcium sulfate-calcium phosphate synthetic bone graft composite in the surgical management of primary bone tumors. Orthopedics. 36, e216-222 (2014).
Johnson, L. J., Clayer, M. Aqueous calcium sulphate as bone graft for voids following open curettage of bone tumours. ANZ J. Surg. 83, 564–570 (2013).
Kelly, C. M., Wilkins, R. M. Treatment of benign bone lesions with an injectable calcium sulfate-based bone graft substitue. Orthopedics. 27, S131-135 (2004).
Liu, B., Lun, D. X. Current application of β-tricalcium phosphate composites in orthopaedics. Orthop. Surg. 4, 139–144 (2012).
Saadoun, S., Macdonald, C., Bell, B. A., Papadopoulos, M. C. Dangers of bone graft substitutes: lessons from using GeneX. J. Neurol. Neurosurg. Psychiatry. 82, e3 (2011).
Koepp, H. E. et al. Biocompatibility and osseointegration of beta-TCP: histomorphological and biomechanical studies in a weight-bearing sheep model. J. Biomed. Mater. Res. 70B, 209–217 (2004).
Xin, R., Leng, Y., Chen, J., Zhang, Q. A comparative study of calcium phosphate formation on bioceramics in vitro and in vivo. Biomaterials. 26, 6477–6486 (2005).
Horch, H.-H., Sader, R., Pautke, C., Neff, A., Deppe, H. & Kolk, A. Synthetic, pure-phase beta-tricalcium phosphate ceramic granules (Cerasorb) for bone regeneration in the reconstructive surgery of the jaws. Int. J. Oral Maxillofac. Surg. 35, 708–713 (2006).
Fini, M. et al. A bone substitute composed of polymethylmethacrylate and alpha-tricalcium phosphate: results in terms of osteoblast function and bone tissue formation. Biomaterials. 23, 4523–4531 (2002).
Zerbo, I. R., Bronckers, A. L., De Lange G. & Burger, E. H. Localisation of osteogenic and osteoclastic cells in porous beta-tricalcium phosphate particles used for human maxillary sinus floor elevation. Biomaterials. 26, 1445–1451 (2005).
Soft Tissue and Bone Tumours. WHO Classification of Tumours. 5th Edition, Volume 3 (2020).
Goslings, J. C. & Gouma, D. J. What is a surgical complication? World J. Surg. 32, 952 (2008).
Kaczmarczyk, J., Sowinski, P., Goch, M. & Katulska, K. Complete twelve month bone remodeling with a bi-phasic injectable bone substitute in benign bone tumors: a prospective pilot study. BMC musculoskeletal disorders 16, 369 (2015).
Cho, H. S. et al. Minimal invasive surgery for unicameral bone cyst using demineralized bone matrix: a case series. BMC Musculoskelet. Disord. 13, 134 (2012).
Hirn, M. et al. Bone defects following curettage do not necessarily need augmentation. Acta Orthop. 80, 4–8 (2009).
Kundu, Z. S., Gupta, V., Sangwan, S. S., Rana, P. Curettage of benign bone tumors and tumor like lesions: a retrospective analysis. Indian J. Orthop. 47, 295–301 (2013).
Perisano, C. et al. Indications for prophylactic osteosynthesis associated with curettage in benign and low-grade malignant primitive bone tumors of the distal femur in adult patients: a case series. J. Orthopaed. Traumatol. 17, 377–382 (2016).
Puri, A., Gulia, A. Curettage of benign bone tumors and tumor-like lesions: a retrospective analysis. Indian J. Orthop. 47, 645–646 (2013).
Gava, N. F., Engel, E. E. Treatment alternatives and clinical outcomes of bone filling after benign tumour curettage. A systematic review. Orthop. Traumatol. Surg. Res. 102966 (2021). doi: 10.1016/j.otsr.2021.102966.
Friesenbichler, J. et al. Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors. Sci Rep. 7, 1736 (2017).
Hirata, M., Murata, H., Takeshita, H., Sakabe, T., Tsuji, Y., Kubo, T. Use of purified beta-tricalcium phosphate for filling defects after curettage of benign bone tumours. Int. Orthop. 30, 510–513 (2006).

No competing interests reported.

Download PDF

Version 1

posted

You are reading this latest preprint version

Artificial bone graft substitutes for curettage of benign and low-grade malignant bone tumors: clinical and radiological experience with Cerasorb

Status:

Version 1

Abstract

Figures

Introduction

Results

Discussion

Methods

Declarations

References

Additional Declarations

Status:

Version 1